化工板块走强、电池板块上涨、医药股活跃……今天A股蓄力中→

Market Overview - The A-share market experienced a collective decline, with the Shanghai Composite Index down by 0.25%, the Shenzhen Component Index down by 0.33%, and the ChiNext Index down by 0.73%. The North Star 50 Index, however, increased by 0.9%. The total trading volume in the Shanghai and Shenzhen markets was 21,635 billion yuan, a decrease of 308 billion yuan from the previous day, with over 2,700 stocks rising [1]. Sector Performance Chemical Sector - The basic chemical sector showed strong performance, with significant increases in fluorine chemicals, phosphorus chemicals, and chemical raw materials, leading to multiple stocks hitting the daily limit. BASF announced a price increase of $200 per ton for TDI products in the Asia-Pacific region (excluding mainland China) due to rising transportation, energy, and regulatory costs. By January 2026, 24% of global TDI production capacity is expected to be offline for maintenance, leading to a continued supply gap in overseas markets [3]. - Huafu Securities reported that the chemical industry is expected to see a recovery in profitability by 2026 after experiencing a downturn in 2025. Supply-side policies are reshaping the competitive landscape, while advancements in AI computing power and humanoid robots are anticipated to drive a new growth cycle [3]. Battery Sector - The battery sector rose by 2.12%, with several constituent stocks reaching their daily limit. Recent advancements in solid-state battery technology were reported by a research team from Qingdao Energy Research Institute, which proposed a "pre-lithiation-bastion" strategy to enhance the performance of silicon anodes in all-solid-state batteries. CITIC Construction Investment indicated that 2026 will be a critical year for the industrialization of solid-state batteries, with multiple automakers and battery companies planning to complete vehicle testing and small-scale production [4]. Pharmaceutical Sector - The pharmaceutical sector was active in the morning but saw a decline in the afternoon. The traditional Chinese medicine sector rose by 1.55%. The Ministry of Industry and Information Technology recently released a development plan for the traditional Chinese medicine industry, aiming for a collaborative development system by 2030, with enhanced supply capabilities and significant technological breakthroughs [5]. - Wanlian Securities noted that since 2025, the traditional Chinese medicine sector has faced performance pressure due to weak sales in pharmacy and hospital channels. The industry is undergoing a transformation period, with a focus on diversified channels, strong brand power, and high clinical value being crucial for future success [6].